A 32-year-old woman presents with a painful vesicular rash on the right lower abdomen and flank in a dermatomal distribution. She reports severe pain and burning sensation. Tzanck smear shows multinucleated giant cells. Regarding the management and clinical course of herpes zoster (shingles), all of the following are true EXCEPT:

Explanation

## Herpes Zoster Management and Complications ### Clinical Context The patient presents with classic dermatomal zoster (shingles) — a reactivation of varicella-zoster virus (VZV) from dorsal root ganglia. The Tzanck smear finding of multinucleated giant cells is consistent with herpesvirus infection (HSV or VZV). ### Correct Statements (Options 0, 1, 2) **Option 0 — Antiviral Therapy:** - **Acyclovir 800 mg five times daily for 7–10 days** is the standard first-line antiviral for uncomplicated zoster in immunocompetent patients. - Alternative agents: valacyclovir 1000 mg three times daily or famciclovir 500 mg three times daily (both have better bioavailability than acyclovir). - Antivirals are most effective when started within 72 hours of rash onset [cite:Park 26e Ch 24]. **Option 1 — Post-Herpetic Neuralgia (PHN):** - **PHN is the most common complication of herpes zoster**, occurring in 10–15% of patients overall but up to 50% in those over 60 years. - Risk increases significantly with age (>50 years is a major risk factor). - PHN can persist for months to years and is difficult to treat [cite:Harrison 21e Ch 187]. **Option 2 — Zoster Vaccination Contraindications:** - **Live attenuated zoster vaccine (Oka strain) is contraindicated in:** - Immunocompromised patients (HIV/AIDS, malignancy, transplant recipients). - Patients on systemic corticosteroids (especially high-dose or prolonged use). - Pregnant women. - The recombinant zoster vaccine (Shingrix) is preferred in these populations as it is inactivated and safe [cite:Park 26e Ch 24]. ### Incorrect Statement (Option 3) — The Answer **Key Point:** **Systemic corticosteroids do NOT significantly reduce the incidence of post-herpetic neuralgia (PHN).** While early corticosteroids may reduce acute inflammation and pain in the acute phase, evidence does NOT support their use for preventing PHN. **Clinical Pearl:** - **Corticosteroids in zoster:** The role of systemic corticosteroids in acute zoster is controversial and NOT routinely recommended. - Some studies suggest corticosteroids may reduce acute pain when combined with antivirals, but they do NOT prevent PHN. - The primary prevention of PHN relies on: 1. Early antiviral therapy (within 72 hours of rash onset). 2. Adequate analgesia during acute phase. 3. Vaccination to prevent zoster (in eligible patients). **High-Yield:** This is a frequent NEET PG trap: students often confuse the possible role of corticosteroids in reducing acute inflammation with prevention of PHN. The evidence does NOT support corticosteroid use for PHN prevention [cite:Harrison 21e Ch 187]. **Warning:** Corticosteroids may actually increase the risk of disseminated zoster in immunocompromised patients and should be avoided in such populations. ### Management Algorithm for Herpes Zoster ```mermaid flowchart TD A[Herpes Zoster Diagnosis]:::outcome --> B{Time since rash onset?}:::decision B -->|< 72 hours| C[Start antiviral therapy]:::action B -->|> 72 hours| D[Consider antiviral if severe or immunocompromised]:::action C --> E[Acyclovir 800 mg 5x daily OR Valacyclovir 1000 mg 3x daily]:::action D --> E E --> F[Adequate analgesia]:::action F --> G{Immunocompetent?}:::decision G -->|Yes| H[Counsel on PHN risk if age > 50]:::action G -->|No| I[Consider IV acyclovir, monitor closely]:::urgent H --> J[Vaccination with Shingrix when healed]:::action I --> J ``` ### Summary: Corticosteroids in Zoster | Aspect | Evidence | |--------|----------| | Reduces acute pain | Possibly, if combined with antivirals; weak evidence | | Prevents PHN | **NO** — not supported by evidence | | Recommended use | Not routine; avoid in immunocompromised | | Risk in immunocompromised | May increase disseminated zoster |